Small molecule drugs that demonstrate target engagement

Orthogon Therapeutics is pioneering innovative therapeutic strategies to address polyomavirus infections, particularly in immune-suppressed populations such as kidney transplant patients. Their drug discovery platform leverages multiple technical innovations, including precise 3D atomic mapping of drug-protein interactions, the development of privileged and target-enriched compound libraries, and the characterization of the kinetics and thermodynamics of these interactions. The company employs a combination of experimental methods and advanced machine learning techniques to enhance the drug discovery process, focusing on the unique challenges posed by polyomaviruses, which are prevalent yet lack effective treatments.

The company is advancing a portfolio of orally administrable antiviral drugs that target unconventional molecular mechanisms associated with polyomaviruses, such as the BK and JC polyomaviruses. These viruses are linked to severe clinical outcomes, including nephropathy and progressive multif

United States

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

Orthogon Therapeutics

Company Details